Published Date: 02 Mar 2023
Many doctors have accused hospitals and large hospitals of opposing quality care and promoting violence. Others disagree.
Read Full NewsThe largest randomized study of a multicancer blood test found no reduction in late-stage cancers, while raising new questions about stage shift, mortality benefit, and population screening.
Interim findings from the phase 3 MonumenTAL-3 trial highlight overall and progression-free survival as well as response rates compared with standard therapy.
1.
TCL1A Protein Identified as Predictor of Blinatumomab Response in Relapsed B-ALL
2.
Is Exercise an Effective Treatment for Prostate Cancer?
3.
Which Risk Model Better Identifies High-Risk Smoldering MM?
4.
Spouses of Cancer Patients May Be at Increased Risk of Suicide
5.
Zebrafish models offer fast, effective guidance for personalized therapies for kids with high-risk cancer
1.
Unlocking the Potential of Lutathera: A Revolutionary Cancer Treatment
2.
Beyond the Battle: Navigating Life After Cancer
3.
The Impact of Microadenoma on Hormonal Health
4.
Exploring the Role of Fecal Leukocytes in Intestinal Health
5.
Oncological Surgery Today: Personalized, Interdisciplinary Approaches to Cancer Care
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
International Lung Cancer Congress®
1.
Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients
2.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma
3.
Exploring the Hospitalization Burden in Refractory and Relapsed ALL
4.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II
5.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation